tirzepatide cardiovascular outcomes trial In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality compared to sitagliptin, but offered no additional benefit over semaglutide. #ESCCongress Tirzepatide for Heart Failure with

1 Skin Clinic Chain), an ISO 9001-2008 certified clinic, is fully dedicated to medical excellence in Cosmetic Dermatology and follows international standards in providing cosmetic and skincare services

Patients participating in trials or accessing retatrutide through research programmes should discuss their specific symptom timeline with their supervising clinician

final data from Phase 3 clinical trials has yet to be released

Injections can still be considered in specific circumstances, such as when a neurological or haematological condition could deteriorate rapidly, or when there are serious concerns that oral treatment will not be taken reliably